Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-deficient cells

Blood

Volumn 124, Issue 1, 2014, Pages 134-141

  Makarona, Kalliopi ^a   Caputo, Valentina S ^a   Costa, Joana R ^a   Liu, Binbin ^b   O'Connor, David ^a   Iskander, Deena ^a   Roper, David ^c   Robertson, Lynn ^c   Bhatnagar, Neha ^a   Terpos, Evangelos ^d   Georgiou, Elisabeth ^e   Papaioannou, Maria ^e   Layton, D Mark ^a   Luzzatto, Lucio ^f   Roberts, Irene ^b   Karadimitris, Anastasios ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; RNA POLYMERASE II; TRANSCRIPTION FACTOR SP1;

AMINO ACID SUBSTITUTION; ARTICLE; B LYMPHOCYTE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME BINDING; EPIGENETICS; ERYTHROID PRECURSOR CELL; EXON; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GPPP GENE; HEMOLYTIC ANEMIA; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MISSENSE MUTATION; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION; UPREGULATION; BIOSYNTHESIS; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; ENZYMOLOGY; GENETIC EPIGENESIS; GENETICS; REAL TIME POLYMERASE CHAIN REACTION;

CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; EPIGENESIS, GENETIC; GLUCOSEPHOSPHATE DEHYDROGENASE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HISTONE DEACETYLASE INHIBITORS; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC;

EID: 84904019058     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-553792     Document Type: Article

References (38)

1. Shahbazian MD, Grunstein M. Functions of sitespecific histone acetylation and deacetylation. Annu Rev Biochem. 2007;76:75-100.
2. Clayton AL, Hazzalin CA, Mahadevan LC. Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell. 2006;23(3): 289-296. (Pubitemid 44128853)
3. Marks PA. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta. 2010; 1799(10-12):717-725.
4. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem. 2005; 96(2):293-304. (Pubitemid 41437862)
5. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr. 2003;133(7 Suppl): 2485S-2493S. (Pubitemid 36828858)
6. Delcuve GP, Rastegar M, Davie JR. Epigenetic control. J Cell Physiol. 2009;219(2):243-250.
7. Almeida AM, Murakami Y, Baker A, et al. Targeted therapy for inherited GPI deficiency. N Engl J Med. 2007;356(16):1641-1647. (Pubitemid 46631673)
8. Caputo VS, Costa JR, Makarona K, et al. Mechanism of Polycomb recruitment to CpG islands revealed by inherited disease-associated mutation. Hum Mol Genet. 2013;22(16): 3187-3194.
9. Gray SG, Qian CN, Furge K, Guo X, Teh BT. Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol. 2004;24(4):773-795.
10. Joseph J, Mudduluru G, Antony S, Vashistha S, Ajitkumar P, Somasundaram K. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene. 2004;23(37):6304-6315. (Pubitemid 39215301)
11. Rada-Iglesias A, Enroth S, Ameur A, et al. Butyrate mediates decrease of histone acetylation centered on transcription start sites and downregulation of associated genes. Genome Res. 2007;17(6):708-719. (Pubitemid 46919708)
12. Wang Z, Zang C, Cui K, et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009; 138(5):1019-1031.
13. Hirono A, Kanno M, Miwa S, Beutler E. Pyruvate kinase deficiency and other enzymopathies of the erythrocyte. In: Scriver CR, Beaudet WS, Valle D, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. Vol. 2. New York, NY: McGraw-Hill; 2001:4637-4664.
14. Luzzatto L, Poggi V. Glucose-6-phosphate dehydrogenase deficiency. In: Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE, eds. Nathan & Oski's Hematology of Infancy and Chilhood. 7th ed. Philadelphia, PA: Saunders; 2009:883-907.
15. Luzzatto L, Mehta A, Vulliamy T. Glucose 6-phosphate deficiency. In: Scriver, Beaudet, Valle, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. Vol. 2. McGraw-Hill; 2001:4517-4554.
16. Beutler E. G6PD deficiency. Blood. 1994;84(11): 3613-3636. (Pubitemid 24362456)
17. Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014;164(4): 469-480.
18. Wells TN, Burrows JN, Baird JK. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010;26(3):145-151.
19. Howes RE, Piel FB, Patil AP, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9(11):e1001339.
20. Chaidos A, Caputo V, Goudevenou K, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014;123(5):697-705.
21. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31(4):e15.
22. Bailey TL, Boden M, Buske FA, et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res. 2009;37(Web Server issue): W202-W208.
23. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26(37):5310-5318. (Pubitemid 47255917)
24. Philippe M, Larondelle Y, Lemaigre F, et al. Promoter function of the human glucose-6- phosphate dehydrogenase gene depends on two GC boxes that are cell specifically controlled. Eur J Biochem. 1994;226(2):377-384. (Pubitemid 24379056)
25. Franzè A, Ferrante MI, Fusco F, et al. Molecular anatomy of the human glucose 6-phosphate dehydrogenase core promoter. FEBS Lett. 1998; 437(3):313-318. (Pubitemid 28511182)
26. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest. 1991;88(5):1613-1621.
27. McGonigle DP, Lalloz MR, Wild BJ, Layton DM. G6PD-Brighton: A new class I glucose-6- phosphate dehydrogenase variant due to a deletion in exon 13. Br J Haematol. 1998; 101(Suppl.1):117.
28. Poggi V, Town M, Foulkes NS, Luzzatto L. Identification of a single base change in a new human mutant glucose-6-phosphate dehydrogenase gene by polymerase-chainreaction amplification of the entire coding region from genomic DNA. Biochem J. 1990;271(1): 157-160. (Pubitemid 20331211)
29. Vulliamy TJ, Kaeda JS, Ait-Chafa D, et al. Clinical and haematological consequences of recurrent G6PD mutations and a single new mutation causing chronic nonspherocytic haemolytic anaemia. Br J Haematol. 1998;101(4):670-675. (Pubitemid 28308516)
30. Georgiou E, Layton M, Karadimitris A. Inherited GPI deficiency: a disorder of histone hypoacetylation. Birth Defects Res C Embryo Today. 2009;87(4):327-334.
31. Perissi V, Jepsen K, Glass CK, Rosenfeld MG. Deconstructing repression: evolving models of co-repressor action. Nat Rev Genet. 2010;11(2): 109-123.
32. Wierstra I. Sp1: emerging roles - beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun. 2008; 372(1):1-13.
33. Morelli A, Benatti U, Gaetani GF, De Flora A. Biochemical mechanisms of glucose-6-phosphate dehydrogenase deficiency. Proc Natl Acad Sci USA. 1978;75(4):1979-1983. (Pubitemid 8337594)
34. Marks PA, Johnson AB, Hirschberg E. Effect of Age on the Enzyme Activity in Erythrocytes. Proc Natl Acad Sci USA. 1958;44(6):529-536.
35. Cancedda R, Ogunmola G, Luzzatto L. Genetic variants of human erythrocyte glucose-6-phosphate dehydrogenase. Discrete conformational states stabilized by NADP 1 and NADPH. Eur J Biochem. 1973;34(1):199-204.
36. Luzzatto L, Testa U. Human erythrocyte glucose 6-phosphate dehydrogenase: structure and function in normal and mutant subjects. Curr Top Hematol. 1978;1:1-70.
37. Olivieri NF, Rees DC, Ginder GD, et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet. 1997;350(9076):491-492. (Pubitemid 27343309)
38. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood. 1994;84(1):339-343. (Pubitemid 24193840)